Stryker’s FDA Approval Accelerates Neck Aneurysm Treatments
On November 9, 2017, Stryker (SYK) announced FDA approval for the Neuroform Atlas Stent System, which is approved for marketing under an HDE.
Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.
On November 28, 2017, Howmedica Osteonics, an orthopedics subsidiary of Stryker (SYK) and Zimmer Biomet Holdings (ZBH), settled a trade secret case.
As of November 30, 2017, in a Reuters survey of 27 investment research companies, ~63% or 17 firms recommended Stryker stock as a “buy.”
Boston Scientific (BSX) announced its deal to acquire Apama Medical and strengthen its electrophysiology portfolio on October 2, 2017.
Since the company’s news of the delay in relaunch of Lotus Edge on November 28, 2017, Boston Scientific (BSX) stock has fallen ~7.8%.
According to Boston Scientific, the delay will have no material impact on the company’s fiscal 4Q17 and 2017 results.
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX’s Lotus devices in Europe and the US on November 28, 2017.
Boston Scientific (BSX) stock fell ~7.5% on November 28, 2017, triggered by the speculation of bad news.
According to a recent Reuters survey, which included eight investment brokerage firms, six (or 75%) of them have recommended a “hold” for VAR stock.
Varian Medical Systems expects to see fiscal 2018 revenue growth in the range of 2%–4%. Its adjusted diluted EPS (earnings per share) for fiscal 2018 is expected to be $4.20–$4.32.
Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.
In fiscal 4Q17, Varian Medical Systems (VAR) registered a gross profit margin of 42.3% of its total sales, representing a decline of 50 basis points.
Varian’s Oncology segment sales in the Americas rose 2%, whereas order growth in the region rose 1% in 4Q17.
Varian Medical Systems (VAR) received FDA (U.S. Food & Drug Administration) approval in June 2017 for its Halcyon system.
Varian Medical Systems (VAR) registered a YoY (year-over-year) sales decline of ~1% in fiscal 4Q17, which was reported on October 25, 2017.
On November 30, 2017, Varian Medical Systems (VAR) was trading at its 52-week high of $111.40. On November 29, it ended trading at $111.20, its highest closing price for the last 52 weeks.
In fiscal 2Q18, Medtronic used a portion of its divestiture proceeds toward stock buybacks. The total share repurchases in the quarter came in at ~$568.0 million.
Medtronic provides solutions to hospitals, which translate the clinical value to economic value for these hospitals.
Medtronic’s TYRX-based infection reduction program is accelerating at a strong pace. The number of accounts under this contract tripled to around 900 hospitals in fiscal 2Q18.